Datar Cancer Genetics Europe GmbH

At Datar Cancer Genetics, we’re proud to be a leading molecular oncology facility with a global team of more than 250 dedicated professionals. Our state-of-the-art laboratories in the UK and India, along with our in-house bioinformatics team, are committed to enhancing clinical data and reporting according to the latest scientific standards. With accreditations from UKAS, ISO 15189, CAP, and CLIA, we ensure the highest quality in our diagnostics. With tests like exacta, we aim to help clinicians and patients worldwide to make more informed decisions, offering access to cutting-edge, personalised cancer care. As we continue to refine our technologies and expand our research, we're proud to collaborate with leading experts in the field to deliver the best possible care for cancer patients worldwide. 🌍 Together, let's transform the future of oncology! #CancerDiagnostics #PrecisionMedicine #PatientCare #DCG #Oncology #LiquidBiopsy #ESMO2024

DCG at SEOM Congress in Madrid Last week, our Business Developer Giulia Crepin had the opportunity to attend the #SEOM Congress in Madrid, where leading oncologists and healthcare professionals gathered to share the latest developments in cancer research, including recent publications and ongoing clinical trials. Events like SEOM are vital for fostering the exchange of knowledge and driving innovation in oncology. By connecting with experts and staying at the forefront of cancer care, we continue to contribute to advancements in the fight against cancer. Let’s keep moving forward, advancing both knowledge and innovation in oncology! #cancer #diagnostics #liquidbiopsy #oncology #precisionmedicine #dcg

DCGE Team Gathering The DCGE team came together a few days ago, and it was truly a fantastic experience! We enjoyed the chance to connect and collaborate. We also took the opportunity to discuss important work topics, sharing ideas and strategies for upcoming projects. Spending quality time together outside of our usual workspace strengthened our bonds and left us feeling inspired and motivated for the exciting work ahead. Thank you to everyone who made this gathering memorable. We’re ready now to bring this positive energy into our upcoming projects as a team! Stefan Schuster, Susanne Funcke, Giulia Crepin, Felix Melchior, Dr., David Reismann, Sandra Henneking #DCGE #dreamteam #work #cancerdiagnostics #teameurope #tegernsee

DCG to Participate at MAP Congress 2024 From October 16-18, the Molecular Analysis for Precision Oncology (MAP) Congress will be held in London, and we’re excited to share our latest findings in the multi-omics domain and its implications for personalised cancer care. Colleagues from DCG will be attending the event and are eager to connect - let’s meet up and explore how we can advance cancer diagnostics together! #dcg #cancer #liquidbiopsy #molecularoncology #diagnostics #precisionmedicine

Datar Cancer Genetics visits Marbella Last week, HC Marbella International Hospital invited us to participate in a scientific session. This provided an excellent opportunity to engage and exchange insights with their talented team. We appreciate the warm hospitality extended to us throughout the event. #cancer #liquidbiopsy #screening #prevention #dcg

DCG expands to Moldova While part of the DCG team is busy in the office and others are representing us at #ESMO2024 in Barcelona, our colleague David Reismann had the honor of being invited to speak at the Congresul de Medicină Internă in Moldova. This prestigious event was organized by the Universitatea de Stat de Medicină și Farmacie and the Societatea Medicilor Interniști din Republica Moldova. Subsequently, Dr. Reismann was interviewed on the innovative potential of liquid biopsy for cancer patients, sharing how Datar can contribute to advancing cancer care in Moldova. We’re excited to have found valuable partners in Moldova who share our vision for improving cancer care and driving innovation in patient treatment. #cancercare #liquidbiopsy #oncology #screening #moldavia #DCG

Final Day at #ESMO2024 Day 4 marks the close of a successful ESMO exhibition. Over the past few days, we’ve had the pleasure of connecting with inspiring individuals, strengthening relationships with valuable partners, and engaging in countless in-depth discussions. We hope this is just the beginning of new collaborations that will drive innovation in cancer care and improve treatment outcomes for patients. We’ll be here until 6.30 pm today, eager for more meaningful conversations and excited for what lies ahead! Stefan Schuster Felix Melchior, Dr. Giulia Crepin Sandra Henneking David Reismann Susanne Funcke #Oncology #Cancer #DCG #liquidbiopsy #transformingcancercare #tissueanalysis

ESMO – Day 3 What made Day 3 at ESMO special? Today, we captured insightful interviews with some experts and filmed videos showcasing our oncology portfolio. Stay tuned – we’ll be sharing these clips on LinkedIn over the coming weeks. Tomorrow is the final day of the ESMO exhibition, and we’ll be at Booth 426 all day. Don’t miss the chance to stop by and chat with us! Stefan Schuster Felix Melchior, Dr. Giulia Crepin Sandra Henneking David Reismann Susanne Funcke #ESMO2024 #Oncology #Cancer #DCG #liquidbiopsy

Transforming Cancer Care at Datar Cancer Genetics At Datar Cancer Genetics, we're dedicated to advancing cancer care. Our cutting-edge solutions primarily focus on liquid biopsy-based analyses, while also offering advanced tissue-based options. Visit us at Hall 3, Booth 426 to explore our portfolio and discover how we're working to make a meaningful impact on cancer diagnosis and treatment. We look forward to discussing how we can collaborate to improve patient outcomes. #ESMO2024 #Oncology #Cancer #DCG #liquidbiopsy #tissueanalysis